STOCK TITAN

Nanobiotix S.A. (NBTX) Stock News

NBTX NASDAQ

Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.

Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.

Rhea-AI Summary

Nanobiotix (NBTX) reported its share capital and voting rights as of October 31, 2026, with 50,968,893 shares outstanding.

Total theoretical voting rights were 54,726,179, while exercisable voting rights totaled 54,704,061. The theoretical count is used to calculate ownership threshold crossings and includes shares whose voting rights have been suspended. The exercisable count excludes shares with suspended voting rights, such as treasury shares held by the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
-
Rhea-AI Summary

Nanobiotix (NBTX) announced that management will participate in investor conferences in London on November 16 and 17, 2026.

Chief Executive Officer Laurent Levy and Chief Financial Officer Arnd Christ will present at the Jefferies Global Healthcare Conference on November 16 at 8:30am ET / 1:30pm GMT. Management will also participate in the UBS Global Biopharma Conference on November 17.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
conferences
-
Rhea-AI Summary

Nanobiotix (NBTX) announced Phase 1 melanoma results showing a 41.7% overall response rate with JNJ-1900 (NBTXR3), radiotherapy and immune checkpoint inhibitors.

The analysis included 24 heavily pre-treated patients with advanced primary cutaneous melanoma resistant to anti-PD-1 therapy. Ten patients responded, including four complete responses; disease control reached 75% (18/24). Median progression-free survival was 6.9 months, and median overall survival was 17.8 months. Responses occurred in injected and non-injected lesions. Investigators considered the safety profile acceptable; no new safety signals were observed.

These preliminary results came from a single-arm study, without a comparison group. An exploratory analysis in eight patients found IL-1β had the largest increase among measured plasma cytokines. Investigators concluded that the findings warrant further evaluation in randomized trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
Rhea-AI Summary

Nanobiotix (NBTX) reported 50,967,610 shares outstanding in its disclosure of share capital and voting rights as of September 30, 2026.

Total voting rights comprised 54,729,543 theoretical voting rights and 54,707,425 exercisable voting rights. The theoretical total, used to calculate threshold crossings, includes shares whose voting rights have been suspended. The exercisable total excludes suspended voting rights associated with shares held in treasury by the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.00%
Tags
none
-
Rhea-AI Summary

Nanobiotix (NBTX) appointed Arnd Christ chief financial officer and a member of its executive board, effective October 1, 2026. He succeeds Bart Van Rhijn, who will step down as chief financial & business officer and executive board member after five years of service.

Christ has spent more than 25 years as chief financial officer of public and private biotechnology companies in Europe and the United States. Most recently, he served as chief financial officer of Immatics from October 2020 until September 2025. His previous CFO roles included InflaRx, MediGene, NovImmune and Probiodrug, and he also served on Immunocore’s supervisory board. His transaction experience includes initial public offerings, licensing deals and fundraising for private and publicly listed biotechnology companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.71%
Tags
none
-
Rhea-AI Summary

Nanobiotix (NBTX) reported first-half 2026 results, including a €34.3 million net loss, and updated its lung cancer studies.

Revenue and other income fell to €5.6 million from €26.6 million a year earlier; the 2025 figure included €21.2 million in one-off, non-cash revenue. The loss widened from €5.4 million. Cash was €110.9 million at June 30, up from €52.8 million at year-end 2025. An approximately €86 million offering closed in May. The company expects its cash to fund operations into 2029.

In a Phase 1 lung cancer study, all 24 patients completed treatment; one-year locoregional control was 79%, with no dose-limiting toxicities. In the Phase 2 CONVERGE study, 6 of 7 patients had an investigator-reported response after the full regimen. The FDA cleared a Phase 3 NANORAY-312 protocol amendment that removed the planned interim analysis and reduced the events required for final analysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
Rhea-AI Summary

Nanobiotix (NBTX) reported its share capital and voting rights position as of August 31, 2026, in line with French market regulations.

The company had 50,941,528 shares outstanding on that date. The total number of theoretical ("gross") voting rights was 54,701,246, including shares with suspended voting rights used for threshold calculations. The total number of exercisable ("net") voting rights at shareholders’ meetings was 54,679,128, excluding treasury shares with suspended voting rights. Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris and listed on Euronext Paris and the Nasdaq Global Select Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
-
Rhea-AI Summary

Nanobiotix (NBTX) reported complete Phase 1 full-cohort results for radiotherapy-activated JNJ-1900 (NBTXR3) in 24 patients with inoperable, locoregionally recurrent non-small cell lung cancer eligible for re-irradiation.

All 24 patients completed JNJ-1900 plus re-irradiation with no dose-limiting toxicities and no Grade 3 or higher adverse events related to JNJ-1900 or the injection procedure. Grade 3 radiotherapy-related adverse events occurred in 33% of patients and Grade 5 radiotherapy-related events in 8%. The recommended Phase 2 dose was set at 33% of gross tumor volume.

At a median 12‑month follow-up (data cutoff August 2026), one-year locoregional control was 79%, one-year local progression-free survival was 61% (median 13.6 months), and one-year overall survival was 70% (median 14.8 months). Investigators concluded that JNJ-1900 may enable clinically meaningful local control at substantially lower re-irradiation doses, and additional enrollment in this trial is planned.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
-
Rhea-AI Summary

Nanobiotix (NBTX) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 12:00 pm EDT (6:00 pm CEST) in New York, NY.

The session will feature Chief Executive Officer Laurent Lévy and Chief Financial and Business Officer Bart Van Rhijn. Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, listed on Euronext Paris and the Nasdaq Global Select Market, and focused on physics-based therapeutic approaches across oncology, bioavailability and biodistribution, and central nervous system disorders. The company holds more than 30 umbrella patents covering three nanotechnology platforms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
none
Rhea-AI Summary

Nanobiotix (Euronext Paris, Nasdaq: NBTX) published its monthly disclosure of share capital and voting rights in line with French regulatory requirements. As of July 31, 2026, the company reports 50,833,462 shares outstanding.

Total voting rights amount to 54,534,179 theoretical (“gross”) and 54,512,061 exercisable (“net”) voting rights. Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, focused on physics-based therapeutic approaches in oncology and other indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.20%
Tags
none

FAQ

What is the current stock price of Nanobiotix (NBTX)?

Nanobiotix (NBTX) last closed at $26.90.

What is the market cap of Nanobiotix (NBTX)?

The market cap of Nanobiotix (NBTX) is approximately $1.4B.